FDA Approves Emrosi, a Breakthrough Rosacea Treatment Outperforming Oracea

A new prescription treatment for rosacea, Emrosi, has received approval from the FDA. The medication targets inflammatory skin lesions in adults suffering from the chronic condition. Rosacea affects millions globally, with over 16 million cases reported in America alone.

Emrosi contains 40 mg of minocycline hydrochloride in a modified-release capsule, combining 10 mg of immediate-release and 30 mg of extended-release formulation. The drug, previously known as DFD-29, was tested in two Phase 3 clinical trials, with results presented at the 2025 Fall Clinical Dermatology Conference.

The trials showed DFD-29 outperformed both a placebo and Oracea, a commonly prescribed rosacea treatment. At Week 16, 62.7% of patients on DFD-29 achieved treatment success, compared to 39.0% on Oracea and 28.2% on placebo. The drug also reduced inflammatory skin lesions more effectively, with a decrease of 19.2 compared to 14.8 for Oracea and 11.3 for placebo.

DFD-29 was well tolerated, with no serious side effects linked to the medication. The most frequently reported issue was mild dyspepsia, occurring in at least 1% of participants. The drug's safety profile supported its approval for widespread use.

Emrosi is now available through specialty pharmacy chains across the US. Patients will require a prescription to access the treatment.

The FDA's approval of Emrosi provides a new option for adults with rosacea. Its proven efficacy in reducing skin lesions and managing symptoms offers a potential improvement over existing therapies. The drug is now accessible to patients through prescription at designated pharmacies.